p> rash, constipation and upper respiratory infection.
Please visit http://www.procrit.com for the full Prescribing Information,
including the Boxed WARNINGS, and for the Medication Guide and Patient
Instructions for Use.
About Ortho Biotech Products, L.P.
Ortho Biotech Products, L.P. is a leading biopharmaceutical company
devoted to helping improve the lives of patients with cancer and with
anemia due to multiple causes, including chronic kidney disease. Since it
was founded in 1990, Ortho Biotech and its worldwide affiliates have earned
a global reputation for researching, manufacturing and marketing innovative
products that enhance patients' health. Located in Bridgewater, N.J., Ortho
Biotech is an established market leader in Epoetin alfa therapy for anemia
management. The company also markets treatments for recurrent ovarian
cancer, rejection of transplanted organs and other serious illnesses. For
more information, visit http://www.orthobiotech.com
'/>"/>SOURCE Ortho Biotech Products, L.P. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 Related medicine technology :1.
Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia2.
A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol3.
Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA8064.
ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials5.
Replidynes Investigational Antibacterial Agent REP3123 Prevents Sporulation in Clostridium difficile6.
Replidynes Investigational Antibacterial Agent REP3123 Prevents Toxin Production in Clostridium difficile7.
Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis8.
Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)9.
KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model10.
Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome11.
Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks